本文選題：良性前列腺增生　切入點：穴位貼敷　出處：《北京中醫(yī)藥大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：良性前列腺增生癥(BPH)是老年男性的一種常見病,臨床主要表現(xiàn)是尿頻、尿急、夜尿增多、排尿困難等,嚴(yán)重影響了老年患者的生活質(zhì)量。目前前列腺增生癥的治療主要包括藥物治療和手術(shù)治療,而前列腺增生常發(fā)生于老年人群,很多患者年齡大、體力衰弱或合并有嚴(yán)重的心肺疾患,難以耐受手術(shù)創(chuàng)傷,而長期單獨藥物治療難以奏效,張耀圣教授通過多年臨床實踐,提出前列腺疾病"分經(jīng)論治"的新理論,認(rèn)為其中前列腺增生與任脈相關(guān),病理以陰質(zhì)結(jié)聚、陽氣虛弱為主,前期根據(jù)此理論進(jìn)行的中藥內(nèi)服臨床試驗取得很好的效果,本次研究是在此理論的基礎(chǔ)上進(jìn)行的一次外治法的研究,即選擇任脈穴位進(jìn)行外治貼敷,其具有簡便易行、易為患者接受、無痛、毒副作用少、患者依從性好等特點,在臨床中發(fā)揮出優(yōu)勢,值得進(jìn)一步的研究和推廣。目的:本次研究通過任脈穴位貼敷聯(lián)合翁瀝通膠囊治療良性前列腺增生癥,并觀察患者IPSS評分、生活質(zhì)量評分、中醫(yī)證候評分的變化,客觀評價任脈穴位貼敷的臨床有效性以及安全性。方法:采用隨機、對照的臨床研究方法,選取良性前列腺增生癥(痰瘀互阻型)患者40例,隨機分為對照組和治療組,對照組服用翁瀝通膠囊,3粒/次,2次/日。治療組在服用翁瀝通膠囊基礎(chǔ)上配合任脈穴位貼敷,貼敷為1次/日。2周為一個療程,共觀察2個療程,即4周。4周后,觀察兩組治療前后患者國際前列腺癥狀評分、排尿癥狀對生活質(zhì)量的影響、中醫(yī)癥狀評分。所有的結(jié)果采用SPSS20.0軟件進(jìn)行統(tǒng)計分析,P0.05表示差異有統(tǒng)計學(xué)意義。結(jié)果:治療兩個療程后,治療組總有效率為85%,對照組總有效率為70%,兩者對比治療組優(yōu)于對照組(P0.05)。兩組在國際前列腺癥狀評分(I-PSS)、排尿癥狀對生活質(zhì)量(QOL)的影響以及中醫(yī)證狀評分方面均較治療前有明顯改善,在I-PSS和QOL方面治療組優(yōu)于對照組,差異有統(tǒng)計學(xué)意義(P0.05)。結(jié)論:服用翁瀝通膠囊可以改善良性前列腺增生患者的臨床癥狀,降低國際前列腺癥狀評分,提高生活質(zhì)量,而配合任脈穴位貼敷則能夠更明顯改善良性前列腺增生患者的臨床癥狀、降低IPSS評分,各方面相比要優(yōu)于對照組。因觀察時間短而且前列腺體積與臨床癥狀無明顯相關(guān)性,所以未對前列腺體積變化做進(jìn)一步統(tǒng)計。本次研究結(jié)果驗證了任脈穴位貼敷對良性前列腺增生癥患者有效性,并且因其臨床的安全性以及廉價、易操作的臨床特點也便于進(jìn)一步的推廣應(yīng)用,而且又驗證了張耀圣教授"前列腺經(jīng)絡(luò)歸屬"的新理論,為下一步進(jìn)行大規(guī)模的臨床研究以及動物實驗研究打下基礎(chǔ)。
[Abstract]:Benign Prostate Hyperplasia (BPH) is a common disease in elderly men. The main clinical manifestations are frequent urination, urgency, increased nocturnal urine, difficulty in urinating, etc. This has seriously affected the quality of life of elderly patients. At present, the treatment of benign prostatic hyperplasia mainly includes drug therapy and surgical treatment, and prostatic hyperplasia often occurs in the elderly, many of whom are older. Physical weakness or severe cardiopulmonary diseases make it difficult to withstand surgical trauma, while long-term drug therapy alone is difficult to work. Professor Zhang Yao-sheng has put forward a new theory of "treating prostate diseases by dividing the meridians and treating them" through many years of clinical practice. It is considered that prostatic hyperplasia is related to any pulse, and the pathology is mainly due to the accumulation of yin and deficiency of yang qi. The clinical trial of Chinese herbal medicine on the basis of this theory in the early stage has achieved very good results. This study is based on this theory of a study of external treatment, that is, choose any pulse point to apply external treatment, its easy to be easily accepted, painless, less toxic and side effects, good compliance of patients, and so on. It is worth further research and popularization in clinical practice. Objective: this study treated benign prostatic hyperplasia with Ren Mai acupoint application and Weng Leitong capsule, and observed the patients' IPSS score and quality of life score. The change of TCM syndrome score, objective evaluation of clinical efficacy and safety of acupoint application of Ren vein. Methods: 40 patients with benign prostatic hyperplasia (phlegm and blood stasis mutual obstruction) were selected by randomized and controlled clinical study. The control group was randomly divided into control group and treatment group. The control group took 3 capsules of Weng Leitong capsule twice a day. The treatment group was treated with Zengmai acupoint application on the basis of Weng Leitong capsule, and the treatment group was applied once a day for 2 weeks as a course of treatment, and 2 courses of treatment were observed. After 4 weeks, 4 weeks later, the international prostate symptom scores and the effect of urination symptoms on the quality of life were observed before and after treatment in the two groups. Scores of TCM symptoms. All the results were statistically analyzed by SPSS20.0 software. Results: after two courses of treatment, the difference was statistically significant. The total effective rate of the treatment group was 85 and the total effective rate of the control group was 70. The treatment group was superior to the control group in P0.05. Both groups were better than the control group in the international prostate symptom score (I-PSSN), the effect of urination symptoms on the quality of life (QOL) and the TCM syndromes score. There was a marked improvement before the treatment. The treatment group was superior to the control group in I-PSS and QOL, and the difference was statistically significant (P 0.05). Conclusion: Weng Li Tong capsule can improve the clinical symptoms of patients with benign prostatic hyperplasia, reduce the international prostate symptom score, and improve the quality of life. The clinical symptoms of patients with benign prostatic hyperplasia can be improved more obviously and the IPSS score can be reduced with the application of acupoint application of Ren Mai, which is better than that of the control group in all aspects. Because the observation time is short and the volume of prostate has no obvious correlation with clinical symptoms, Therefore, no further statistics were made on the changes of prostate volume. The results of this study confirmed the effectiveness of Ren Mai acupoint application in patients with benign prostatic hyperplasia, and because of its clinical safety and low cost, The easy-to-operate clinical features are also convenient for further popularization and application, and the new theory of Professor Zhang Yao-sheng 's "the attribution of the prostate meridian" is verified, which lays the foundation for the next large-scale clinical research and animal experimental research.
【學(xué)位授予單位】：北京中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R277.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李晨;;火針治療前列腺增生癥臨床觀察[J];上海針灸雜志;2016年12期

2 張耀圣;李彩芬;;論男子胞[J];中醫(yī)雜志;2016年24期

3 張春和;李焱風(fēng);秦國政;申吉泓;徐波;趙凡;張富剛;楊毅堅;陳天波;丁世霖;鄒建東;;前列通竅膠囊治療腎虛瘀阻型前列腺增生癥87例臨床研究[J];中華中醫(yī)藥雜志;2016年10期

4 程勇謀;莫耀良;譚靜;王曉珊;;鹽酸坦索羅辛治療前列腺增生的臨床療效[J];北方藥學(xué);2016年02期

5 李曉京;魏艷紅;沈司京;張蕾;;非那雄胺治療良性前列腺增生癥的安全性及療效評價[J];中國醫(yī)院用藥評價與分析;2016年01期

6 張玉軍;;癃閉舒膠囊聯(lián)合坦索羅辛治療良性前列腺增生46例療效觀察[J];世界中西醫(yī)結(jié)合雜志;2016年01期

7 居小兵;顧小箭;張征宇;衛(wèi)中慶;徐卓群;繆惠東;周偉民;徐仁芳;程斌;馬建國;牛天力;瞿平;薛波新;張煒;;鋸葉棕果實提取物軟膠囊治療良性前列腺增生的有效性和安全性分析[J];中華男科學(xué)雜志;2015年12期

8 陳本善;周善康;;前列散治療老年良性前列腺增生61例臨床觀察[J];中國民族民間醫(yī)藥;2015年21期

9 劉理濤;劉國雄;喬西民;;良性前列腺增生的外科治療技術(shù)進(jìn)展[J];中國醫(yī)藥指南;2015年30期

10 王勇;孫大林;金保方;張新東;夏國守;徐福松;;補腎導(dǎo)濁顆粒治療良性前列腺增生癥65例的臨床研究[J];中華中醫(yī)藥雜志;2015年10期

，

本文編號：1609562